Quantcast

Latest antibodies Stories

2014-04-03 12:30:00

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth SummaryGBI Research has released the pharma report "Monoclonal...

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-04-03 08:22:27

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/gw6znv/the_engineered ) has announced the addition of the "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective...

2014-03-31 08:31:02

SAN FRANCISCO and WALTHAM, Mass., March 31, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these...

2014-03-28 08:26:41

MONROVIA, Calif., March 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific antibody programs at the Annual Summit on Practical and Emerging Trends in Multiple Myeloma being held in Whistler, British Columbia, Canada. The discussion featured Xencor's bispecific approach...

2014-03-27 08:34:12

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi's iCAPS platform LA JOLLA, Calif. and SHANGHAI, March 27, 2014 /PRNewswire/ -- RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of...

2014-03-26 23:24:54

Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal Antibodies and Fc:Fusion Proteins Geneva, Switzerland (PRWEB) March 26, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s chief scientific officer, Pierre-Allain Girod, Ph.D., will present, “Selexis SURE CHO-Mplus™...

2014-03-24 08:28:11

MONROVIA, Calif., March 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 9:30 a.m. EDT at the Millennium Broadway Hotel...

2014-03-18 08:32:26

Telephus Advances TPH 101 Program Towards Candidate Selection SAN DIEGO, March 18, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, and Telephus Medical LLC, a leader in the development of vaccine products to prevent periprosthetic joint infections and accompanying osteomyelitis in orthopedic procedures, today announced that BioAtla has successfully completed a key protein engineering phase of Telephus'...

2014-03-16 16:20:46

CAMBRIDGE, England, March 16, 2014 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse(TM) (http://dx.doi.org). Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related